An increasing body of evidence suggests that increased expression of PAK5 was observed in a variety of human malignancies including breast cancer, colorectal cancer [20–22], stomach cancer [3, 23], pancreatic cancer, neuroblastoma [21, 24], osteosarcoma [25] and epithelial ovarian cancer [26]. Here, PAK5 is linked to osteosarcoma.